These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 12523079)

  • 21. [A new critical report on coxiber].
    Lindberg M
    Ugeskr Laeger; 2003 Feb; 165(7):701-2. PubMed ID: 12617054
    [No Abstract]   [Full Text] [Related]  

  • 22. [Insights and views about cardiovascular safety of COX2 inhibitors].
    Wallentin L
    Lakartidningen; 2005 Feb 28-Mar 6; 102(9):666, 668, 671. PubMed ID: 15804041
    [No Abstract]   [Full Text] [Related]  

  • 23. Coxib toxicity: a likely class effect.
    Prescrire Int; 2005 Feb; 14(75):22. PubMed ID: 15751177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Coxib debate on thin ice].
    Järhult B
    Lakartidningen; 2005 Mar 7-13; 102(10):788-9; discussion 789-90. PubMed ID: 15839175
    [No Abstract]   [Full Text] [Related]  

  • 25. Why don't we initiate more large simple randomized controlled trials?
    Wright JM
    CMAJ; 2003 Nov; 169(11):1170-1. PubMed ID: 14638653
    [No Abstract]   [Full Text] [Related]  

  • 26. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Smith ER
    Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug testing. Massive trial of Celebrex seeks to settle safety concerns.
    Couzin J
    Science; 2005 Dec; 310(5756):1890-1. PubMed ID: 16373546
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Couzin J
    Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
    [No Abstract]   [Full Text] [Related]  

  • 29. What price pain relief?
    Hochman JS; Shah NR
    Circulation; 2006 Jun; 113(25):2868-70. PubMed ID: 16785335
    [No Abstract]   [Full Text] [Related]  

  • 30. [Expectations and obligations].
    Haug C
    Tidsskr Nor Laegeforen; 2002 Jun; 122(17):1637. PubMed ID: 12555600
    [No Abstract]   [Full Text] [Related]  

  • 31. [Capsule endoscopy study of gastrointestinal tolerance. Coxibes superior to NSAID plus antacid].
    MMW Fortschr Med; 2004 Mar; 146(10):43. PubMed ID: 15347082
    [No Abstract]   [Full Text] [Related]  

  • 32. [Alleviating pain and preventing inflammation with selective COX-2 inhibitors. Prescribing with confidence in the future].
    MMW Fortschr Med; 2005 Mar; 147(9):12. PubMed ID: 15794346
    [No Abstract]   [Full Text] [Related]  

  • 33. [Really only Vioxx?].
    Heinzl S
    Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229
    [No Abstract]   [Full Text] [Related]  

  • 34. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis.
    Eisen GM; Goldstein JL; Hanna DB; Rublee DA
    Aliment Pharmacol Ther; 2005 Mar; 21(5):591-8. PubMed ID: 15740543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
    Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J
    Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850
    [No Abstract]   [Full Text] [Related]  

  • 36. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
    MMW Fortschr Med; 2003 Mar; 145(11):60. PubMed ID: 12688204
    [No Abstract]   [Full Text] [Related]  

  • 37. Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
    Epstein RA
    Yale J Health Policy Law Ethics; 2005; 5(2):741-70. PubMed ID: 16052898
    [No Abstract]   [Full Text] [Related]  

  • 38. A proposal for evaluation of platelet aggregation and adhesiveness for clinical trials with cyclooxygenase inhibitors and nonsteroidal antiinflammatory drugs.
    Atik M
    J Am Coll Surg; 2005 Aug; 201(2):263-4. PubMed ID: 16038825
    [No Abstract]   [Full Text] [Related]  

  • 39. Cyclooxygenase and nitric oxide systems in the gut as therapeutic targets for safer anti-inflammatory drugs.
    Whittle BJ
    Curr Opin Pharmacol; 2004 Dec; 4(6):538-45. PubMed ID: 15525540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A letter which will not change my prescribing patterns].
    Holmberg K
    Lakartidningen; 2002 Nov; 99(48):4906. PubMed ID: 12523081
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.